Mr. Stefano Picone reports

CONAVI MEDICAL CORP. ANNOUNCES CLOSING OF $20M PUBLIC OFFERING

Conavi Medical Corp. has closed its previously announced upsized equity offering for aggregate gross proceeds of $20-million.

The net proceeds from the offering will be used to advance and complete the development and preclinical testing of its Novasight 3.0 technology, with the goal of submitting a 510(k) clearance application to the U.S. Food and Drug Administration in Q3 (third quarter) of 2025. The company also intends to use the net proceeds for working capital and other general corporate purposes.

Bloom Burton Securities Inc. acted as sole and exclusive agent for the offering. Under the offering, subscribers either purchased common shares at 40 cents per common share or prefinanced common share purchase warrants for 39.999 cents per prefinanced common share purchase warrant. Investors purchased a total of 50 million securities (consisting of 32.5 million common shares and 17.5 million prefinanced warrants) for gross proceeds of $20-million. Each prefinanced warrant issued in lieu of a common share at the election of a subscriber entitles the holder thereof to acquire one common share at an exercise price of 0.001 cent per common share. The prefinanced warrants will not expire.

In Canada, the securities purchased pursuant to the offering were qualified for sale by way of a short form prospectus dated April 15, 2025, which was filed in British Columbia, Alberta and Ontario. The securities were purchased by way of private placement in the United States, pursuant to exemptions from the registration requirements under the U.S. Securities Act of 1933 and pursuant to all applicable U.S. state securities laws. In addition, the securities were also sold by way of private placement in certain other jurisdictions outside of Canada and the United States pursuant to and in compliance with applicable securities laws.

CPOINT Capital Corp., an insider of the company, purchased 625,000 common shares under the offering and Juno Pharmaceuticals LP, an insider of the company, purchased 1.25 million common shares under the offering. The subscriptions for common shares by CPOINT Capital and Juno Pharmaceuticals are related party transactions within the meaning of applicable Canadian securities laws. The subscriptions by such insiders are exempt from the formal valuation and minority approval requirements applicable to related party transactions on the basis that the value of the transactions insofar as they involve related parties is less than 25 per cent of the company's market capitalization. The board of directors of the company has approved the offering. A material change report in respect of the related party transactions could not be filed earlier than 21 days prior to the closing of the offering due to the limited time between the commitment by such insiders to purchase the subject common shares and the closing of the offering.

About Conavi Medical Corp.

Conavi Medical is focused on designing, manufacturing and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid system is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid system has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare.

We seek Safe Harbor.